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Proteinlevelswithinsignal transduction pathwaysvarystronglyfromcelltocell.Here,weanalysed
how signalling pathways can still process information quantitatively despite strong heterogeneity
in protein levels. We systematically perturbed the protein levels of Erk, the terminal kinase in
the MAPK signalling pathway in a panel of human cell lines. We found that the steady-state phos-
phorylation of Erk is very robust against perturbations of Erk protein level. Although a multitude
of mechanisms exist that may provide robustness against ﬂuctuating protein levels, we found
that one single feedback from Erk to Raf-1 accounts for the observed robustness. Surprisingly,
robustness is provided through a fast post-translational mechanism although variation of Erk levels
occurs on a timescale of days.
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Introduction
Mammalian cells harbour a complex and highly interlinked
signal transduction network that relays information from the
outside of the cell to the inside, thereby controlling different
processes such as cytoskeletal reorganisation, translation
and the action of transcription factors. One of the central
challenges in understanding how cells process information in
order to respond adequately to their environment is to
understand how the signalling network deals with uncertainty
and the noise inherent to biochemical processes. The role of
noise in signalling networks due to stochasticity of the
biochemical reactions has been addressed in detail during
the last decade (Elf and Ehrenberg, 2003; Bhalla, 2004;
Hornung and Barkai, 2008; Bruggeman et al, 2009). Signal
transduction is often realised by reversible post-translational
modiﬁcations. Although the noise level due to these post-
translational modiﬁcation events can be relatively high, the
timescale of ﬂuctuations is usually considered too small to be
transmitted to gene expression (Bruggeman et al, 2009) and
will therefore hardly inﬂuence major cellular decisions.
However, increasing evidence suggests that the most impor-
tant source of uncertainty in mammalian signal transduction
is noise in the expression of signalling proteins. Even clonal
populations display strong cell-to-cell variations of the level
of the same protein with a s.d. of 20–30% of the mean
(Sigal et al, 2006). These ﬂuctuations of protein concentra-
tions have been shown to inﬂuence major cellular decisions,
such as apoptosis (Spencer et al, 2009). For Erk2, the terminal
kinase of the mitogen-activated signal transduction (MAPK)
pathway, strong variations of the protein level have been
found when single cells are compared with each other.
Cells within the lowest and highest 10% percentile exhibit
a three-fold difference in Erk2 levels, respectively (Cohen-
Saidon et al, 2009). In light of these observations, it appears
surprising that a biochemical machinery exhibiting large
differences and ﬂuctuations of the levels of its components
is nevertheless capable of processing information reliably.
One would rather expect that cells might respond very hetero-
geneouslytothesamestimulus,dependingontheintracellular
levels. Yet, the MAPK pathway is centrally involved in cellular
decision-making, and small quantitative differences in path-
way activity can result in large changes in cellular phenotype
(Ghiglione et al, 1999; Santos et al, 2007; Blu ¨thgen and
Legewie, 2008; Nakakuki et al, 2010). Importantly, Erk activity
is also a very sensitive gate-keeper in the G1/S transition
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directly linked to cell growth (Leﬂoch et al, 2009). Despite
the observed variations in Erk levels, imprecise regulation of
the cell cycle and growth seems implausible. This suggests
that the signalling network is equipped with mechanisms that
render the biological pathway readouts robust against varia-
tions of its components.
For various signal transduction networks, different design
principles have been identiﬁed that confer robustness to the
network against typical perturbations of its constituents (for
review, see Stelling et al, 2004). For example, it has been
shown that the Drosophila segment polarity network is very
robust against ﬂuctuations in the kinetic properties of its
components (von Dassow et al, 2000). Negative feedback
is a very frequent motif found to provide robustness, for
example, in gene regulatory networks (Becskei and Serrano,
2000), in baker’s yeast galactose network (Acar et al, 2010)
and in bacterial chemotaxis (Alon et al, 1999). While these
examples show how developmental pathways, simple eukar-
yotes and bacteria deal with uncertainty, little is currently
known about how robustness is realised in the mammalian
signal transduction network. It is of central importance to
identify which principles govern robustness in mammalian
signalling pathways, since perturbation of these pathways
by pharmacological agents nowadays is a main strategy
in ﬁghting diseases including cancer (Zhang et al, 2009).
Since many unknown obstacles can prevent efﬁcient inhibi-
tion of signalling pathways in cancer, perturbation strate-
gies need to be identiﬁed that successfully manipulate the
signalling network and at the same time are not hampered
by the natural robustness of the system. Moreover, identiﬁca-
tion of reduced robustness, due to oncogenic mutations in
cancer cells, will increase the chance of successful targeted
intervention.
We, therefore, set out to investigate how robustness to
protein expression is realised in one of the best-studied
mammalian signal transduction system, the MAPK signal
transductionpathway.Wechoseacombinedexperimentaland
theoretical approach to determine how a change in total
protein concentration of the terminal kinase in this pathway,
Erk, translates into changes of its phosphorylated active form,
and which consequences arise for signalling and pathway
intervention upstream of Erk.
Results
Mathematical analysis predicts linear relation
between protein level and activity
TheactivityoftheterminalkinaseoftheclassicalMAPKsignal
transduction pathway, Erk, is controlled by competition of
phosphorylation and dephosphorylation of a threonine/tyro-
sine motive. Phosphorylation is carried out by the kinase Mek,
and Erk is dephosphorylated by a multitude of phosphatases.
The biochemical processes involved in Erk phosphorylation
have been elucidated in depth. It has been shown that
phosphorylation by Mek proceeds sequentially, tyrosine being
phosphorylated before threonine (Schilling et al, 2009).
Additionally, Mek tends to detach from Erk before carrying
out the second phosphorylation (Ferrell and Bhatt, 1997), that
is, phosphorylation is not processive. Dephosphorylation is
lesswellstudied,butitislikelythatitfollowsasimilarscheme.
Furthermore, it has been demonstrated that both isoforms of
Erk, Erk1 and Erk2, are nearly identical in their biochemical
properties (Yoon and Seger, 2006; Leﬂoch et al, 2008; Voisin
et al, 2010). From this information, we developed a simple
mathematical description of Erk activation where the steady-
state level of double-phosphorylated Erk (ppErk) is dependent
on the phosphorylation rate (km), the dephosphorylation rate
(kp) and the total level of Erk (ErkT) in the following form
(derivation see Supplementary information):
ppErk ¼ ErkT 
km
kp
 2
1 þ km
kp

þ km
kp
 2 : ð1Þ
This equation shows that the double-phosphorylated form
of Erk (ppErk) is predicted to be non-linearly dependent on
the phosphorylation and dephosphorylation rates. The exact
form of the second term on the right hand side is being
determined by the details of the kinetic scheme, such as
the number of phosphorylation sites, or whether there is
cooperativity between phosphorylation of the different sites.
However, the model predicts a linear dependence of ppErk
on protein concentration ErkT, independent of the precise
kinetic mechanism as long as the kinase Mek and the
phosphatases are not strongly saturated. Consequently, 30%
variation in Erk levels, for example, due to gene expression
noise, would translate into 30% variation in phosphorylation
of Erk in a population of clonal cells (see Figure 1A and B,
green lines).
In order to quantify how ppErk depends on ErkT,i ti s
instrumental to use the normalised derivative, R:
R ¼
ErkT
ppErk
dppErk
dErkT
: ð2Þ
This coefﬁcient is very similar to response coefﬁcients from
modularresponseanalysis,whichdeﬁnesinformationtransfer
in systems where no mass-ﬂow exists between variables
(Kholodenko et al, 2002). Since the mathematical properties
and, most importantly, the interpretation of the above deﬁned
coefﬁcient are very similar, we will refer to it as response
coefﬁcient. For our model, it equates to one, since the
phosphorylated form of the protein changes proportionally
with the total protein concentration. In this case, the pathway
is non-robust. Values below 1 denote increased robustness of
the phosphorylated form, and R¼0 indicates perfect insensi-
tivity of ppErk against changes in Erk levels.
Examples of theoretical ppErk levels due to variations in
total Erk concentration for a hypothetical non-robust, a
partially robust and fully robust system are depicted in
Figure 1A. Taking a realistic distribution of total Erk
concentrations in single cells (log-normal with s.d. of 20%
of mean), a non-robust system would show strong varia-
tionsinppErklevels(Figure1B),withsomecellsshowingvery
low levels and other levels more than two-fold higher than
the mean. In contrast, a system with increased robustness
(e.g., R¼1/3, red lines in Figure 1A and B) would show a
strongly reduced spread of ppErk levels. A fully robust system
(R¼0, blue lines in Figure 1A and B) would virtually eliminate
variations in ppErk levels between clonal cells.
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Erk levels
In order to test whether phosphorylated Erk is linearly
dependent on the level of the protein, as our initial model
suggests, we took advantage of the fact that cells express two
isoforms of Erk, Erk1 and Erk2. These isoforms are expressed
at different levels, with Erk2 being the dominantly expressed
isoform (Leﬂoch et al, 2008; Voisin et al, 2010). By siRNA-
mediated knockdownof each isoform alone and both isoforms
together we could perturb the total level of Erk to different
extends. We performed such knockdown experiments in
LIM1215 cells, colorectal cancer cells without mutations
upstream or within the MAPK signalling pathway (Whitehead
et al, 1985; Jhawer et al, 2008; and data not shown).
Subsequently, we quantiﬁed the levels of Erk and ppErk using
quantitative western blotting (details see Materials and
methods).
Figure 1C summarises the results of this experiment. We
expected from the mathematical model that Erk phosphoryla-
tion is proportional to the total Erk concentration. However,
our western blot analyses clearly show that ppErk levels
deviate strongly from the model prediction. The data rather
suggest that even a reduction of Erk levels by 80% will only
leadtoamodestdecreaseofphosphorylatedErkdownto50%,
thus indicating that ppErk is rather robust against variations in
Erk levels. By linear regression of the logarithmic values we
estimate R¼0.43 (ﬁt shownassolid line). Arepresentativeblot
is shown in Supplementary Figure S1.
Three possible mechanisms for robustness
Surprised by the high robustness of phosphorylated Erk levels
towards strong variations in total Erk levels, we asked which
mechanisms maylead tothis remarkablylowsensitivityofErk
phosphorylation. We speculated that three properties of this
signalling pathway may lead to such low sensitivity and
analysed the consequences of these potential mechanisms
further utilising mathematical models. These properties are as
follows:
Saturated phosphorylation by Mek
It is known that Mek is only phosphorylated at low levels
(Leﬂoch et al, 2008), and that the docking interaction between
Mek and Erk can be tight (Kolch, 2000). Therefore, Mek might
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Figure 1 Robustness of MAPK signalling. (A) Mathematical analysis of Erk phosphorylation kinetics suggests that the phospho-Erk level depends linearly on Erk
protein concentration (green line, no robustness). The red line shows hypothetical partial robustness, where phosho-Erk level depends sublinearly on Erk. The blue line
corresponds to a fully robust system, where phosho-Erk can fully compensate loss of Erk. (B) The consequences of variability in Erk expression (grey) on phospo-Erk
expression for a non-robust, partially robust and fully robust system are shown. (C) Steady-state phospho-Erk level of LIM1215 cells depends only weakly on Erk
concentration. Each dot shows quantiﬁed pan-isoform phospho-Erk and Erk levels from western blots of cells treated with siRNA against Erk1 or Erk2 alone, Erk1 and
Erk2 in combination in percent of the scrambled control. (D) Possible mechanisms providing robustness illustrated for knockdown of Erk2: competition for upstream
kinase Mek, where loss of Erk2 results in higher access of Erk1 to Mek; post-translational negative feedback, where loss of Erk2 results in relieve of negative feedback
and therefore stronger upstream signalling; and transcriptional negative feedback, where knockdown of Erk2 results in decreased concentrations of deactivating
phosphatases. Source data is available for this ﬁgure at www.nature.com/msb.
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boundto Erk. Inthat case, loweringthetotalErkconcentration
would make Mek more accessible to the remaining Erk
molecules and increase the probability of their phosphoryla-
tion (depicted in Figure 1D, left panel). In the following, we
show that already a simple model that assumes enzymatic
activation of Erk by a single phosphorylation event entails
robustness of the level of phosphorylation or a response
coefﬁcient smaller than 1, respectively. The model reads:
pErk   kp ¼
um  ð ErkT   pErkÞ
KM þ ErkT   pErk
: ð3Þ
The associated response coefﬁcient reads:
R ¼
ErkT   KM   1  
dpErk
dErkT

ðErkT   pErkÞðKM þ ErkT   pErkÞ
: ð4Þ
Since
dpErk
dErkT ranges between 0 and 1 (see Supplementary
information), and typically only a small fraction of Erk is
phosphorylatedin steadystate(pErk   ErkT), Rsimpliﬁes to:
R  
ErkT   KM   1  
dpErk
dErkT

ErkT   KM þ Erk
2
T
o1: ð5Þ
The prediction of the model thus is that the pathway is
robust if pMek levels are low and unaffected by a change in
Erk levels. Furthermore, increasing concentrations of Mek
will reduce saturation of Mek, and would therefore increase
ppErk levels.
Post-translational feedback regulation
The MAPK signalling pathway is regulated by post-transla-
tionalfeedbackatmanydifferentlevels.Erkhasbeenshownto
phosphorylate and thereby inactivate several adaptor mole-
cules, and Erk deactivates Raf-1 by phosphorylating inhibitory
sites (Dougherty et al, 2005; Yoon and Seger, 2006; Dhillon
et al, 2007). The consequence of such negative feedback when
reducing the concentration of one of the isoforms is illustrated
in Figure 1D. Since the amount of ppErk is reduced, feedback
inhibition is relaxed, and consequently the level of pMek
increases. This in turn increases the phosphorylation of the
remaining Erk isoform and the residual protein of the targeted
isoform, therebypartiallycompensating for theloss of protein.
A mathematical analysis of the feedback system yields that
the response coefﬁcient R can be expressed in terms of the
feedback strength. If one adds a negative feedback to the
simplest model of Equation (1), the steady state of the system
can be described by two variables, pMek and ppErk:
ppErk ¼fðErkT; pMekÞ
pMek ¼gðppErkÞ:
ð6Þ
Calculating R from these equations yields:
R ¼
1
1   r1r2
; ð7Þ
withthelocalresponsecoefﬁcientr1¼(qlnpMek)/(qlnppErk)
quantifying the strength of the feedback, and r2¼(q ln ppErk)/
(q ln pMek) quantifying the ampliﬁcation from pMek to
ppErk. Since the feedback and consequently r1 is negative, an
increased strength of the negative feedback reduces R. There-
fore, negative feedback may confer robustness to ppErk levels.
If negative feedback is the cause of robustness then we
would expect that, |r1 r2|41, since we previously estimated
the global response coefﬁcient R to be 0.43. Therefore, we
would predict that a feedback needs to be strong, that is,
changes in ppErk are ampliﬁed along the feedback loop.
Transcriptional feedback
Erkisnotonlyregulatedviafeedbacksatthepost-translational
level, but also by transcriptional negative feedback loops.
So-called dual-speciﬁcity phosphatases (DUSPs) constitute
a protein family, which can dephosphorylate threonine and
tyrosineresidues.AsubfamilyoftheseDUSPsisabletobindto
Erk and is involved in Erk dephosphorylation, mainly DUSPs
2, 4, 5, 6, 7 and 9 (Patterson et al, 2009). The expression of
several of these DUSPs is controlled by transcription factors
downstream of Erk thereby constituting negative feedback
regulation (Amit et al, 2007; Legewie et al, 2008). Negative
transcriptional feedback may provide robustness similar to
post-translational feedback. If Erk concentration is reduced,
expressionofthe inhibitory proteinwillbe loweredand inturn
the remaining Erk will be hyper-phosphorylated. Analogously
to the post-translational feedback, also the transcriptional
feedback needs to be strongly amplifying.
Since each of the three mechanisms may help in compensat-
ing the changes in total Erk levels, we set out to investigate
which of them, either alone or in combination, does confer
robustness to Erk phosphorylation.
Transcriptional negative feedback regulation
via DUSPs is not involved in robustness of
Erk phosphorylation
We ﬁrst investigated whether the observed robustness of
ppErk, on a timescale of days, can be explained by transcrip-
tional negative feedback. In order to test whether the observed
robustness can be attributed to feedback regulation by DUSPs,
we analysed Erk-mediated regulation of DUSPs on the
transcriptional level in LIM1215 cells. We applied the Mek
inhibitor U0126 to the cells, and observed that the phospha-
tases DUSP5, DUSP6 and DUSP7 are downregulated, thereby
constituting a negative feedback (Figure 2A).
Since we identiﬁed three DUSPs as feedback regulators of
Erk, we performed quantitative RT–PCR analyses of these
DUSPstogetherwithsevenotherDUSPgenesafterknockdown
of both Erk isoforms. The results, as depicted in Figure 2B,
show that none of the classical DUSPs displayed a strong
downregulation 48h following Erk knockdown. Therefore,
although transcriptional negative feedback regulation via
DUSPs is present in these cells, such feedback via DUSPs can
be ruled out as a mechanism for the observed robustness in
Erk phosphorylation.
Post-translational feedback via Raf-1 mediates
robustness
As the next hypothesis, we asked whether post-translational
feedback is involved in compensating the reduction of Erk
levels. To investigate this, we took advantage of a panel of
colon cancer cells that harbour different mutations upstream
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transductionpathwayatdifferentlevels.Whereasthecelllines
HT29 and RKO have an activating mutation in B-Raf (V600E),
the cell lines HCT116 and SW480 contain mutations in Exon 2
of the K-Ras gene (D13E and G12V, respectively). As control,
the LIM1215 cell line is used that is devoid of KRAS or BRAF
mutations. The left panel of Figure 3A shows the position of
theseproteinsintheMAPKsignallingpathway.K-Rasactivates
the pathway primarily via Raf-1, whereas B-Raf activates Mek
and signals independently of Raf-1 (Karreth et al, 2009).
In consequence, we expected that if a post-translational
feedback acts upstream of Ras, only LIM1215 cells, which are
devoid of mutations in the pathway, should show robustness
in ppErk levels. If the feedback acts at Raf-1, the expectation is
that Ras-mutated cells still show robustness, but B-Raf-
mutated cells would not.
We performed knockdown experiments of the two isoforms
of Erk in these cells and measured the total Erk level as well as
the levels of phosphorylated Erk1 and Erk2. As a ﬁrst result,
this analysis showed that there is no compensatory regulation
between Erk1 and Erk2 proteins, that is, if Erk1 protein level is
lowered, this is not compensated by Erk2 protein expression
and vice versa, independently of the cellular background (see
Figure 3B).
Wethen calculatedthetotalamount ofErkandphospho-Erk
after knockdown in this panel of cell lines. Again, we then
analysed whether ppErk depends non-linearly on Erk con-
centration. Strikingly, we ﬁnd that in both cell lines with a B-
Raf V600E mutation, robustness is lost, that is, the phosphor-
ylation of Erk decreases linearly with removal of Erk
(Figure 3C, blue data points). In stark contrast, cells harbour-
ing a mutation in Ras show a non-linear relation between
ppErkandErk(Figure3C,reddatapoints).Byregressionofthe
logarithmicvalues,weestimate theglobalresponsecoefﬁcient
tobeR¼0.36andR¼0.20forHCT116andSW480,respectively.
The western blots (Figure 3D; Supplementary Figure S1) show
consistently a strong increase in Erk1 phosphorylation if Erk2
is knocked down, for cells with wild-type B-Raf, and un-
changed Erk1 phosphorylation if B-Raf is mutated (see
Supplementary Figure S2). These data suggest that there is
an absence of robustness in B-Raf-mutated cells, whereas Ras-
mutated cells or cells harbouring wild-type Raf and Ras show
robustcompensationoflossinErkexpression.Wehypothesise
that this is due to a negative post-translational feedback
targeting Raf-1, as mutated B-Raf triggers MAPK activity
independently of Raf-1.
Inordertofurtherinvestigatethehypothesisthatrobustness
is caused by a feedback to Raf-1, we measured pMek levels
in our cell line panel after knockdown of Erk isoforms.
If feedback regulation is indeed mediated by Raf-1 or another
component between Ras and Mek, one would expect an
increaseofpMeklevelsafterknockdownoftheErkisoforms in
Ras-mutatedcells.Incontrast,onewouldexpectnoincreaseof
pMek in B-Raf-mutated cells. As expected, pMek levels
increase in Ras-mutated cells after knockdown of Erk1, Erk2
or both isoforms in Ras-mutated cells (Figure 3E, red bars).
The increase in pMek level is low following Erk1 suppression,
higher after Erk2 suppression and highest following Erk1/2
double knockdown. This indicates that the effect of the
feedback increases monotonically with decreased Erk protein
abundance. In contrast, no increase in pMek after Erk
knockdown was observed in B-Raf-mutated cells (Figure 3E,
blue bars).
In Ras-mutated cells, Raf-1 is feedback controlled
whereas Ras is not
In order to conﬁrm that Raf-1 is feedback controlled in colon
cancer cell lines, we applied the Mek inhibitor U0126 and its
vehicle control DMSO for 24h to HT29 and HCT116 cells to
abrogate Erk activity, and monitored the Raf-1 phosphoryla-
tion status using antibody recognising the cluster of Erk
phosphorylation sites within the hinge region of Raf-1
(Dougherty et al, 2005). In agreement with the chronic
activation of the Erk pathway in these colon cell lines, Raf-1
displays a prominent phosphorylation at these residues in the
control samples, but not in U0126-treated cells (Figure 4A, top
row). Furthermore, the detection of total Raf-1 demonstrated
that the application of U0126 accelerated its electrophoretic
mobility (Figure 4A, middle row), which is in full agreement
with various previous studies using the chemically distinct
MEK inhibitor PD98059 (Wartmann et al, 1997; Dougherty
et al, 2005). Interestingly, Raf-1 is also feedback controlled
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Figure 2 Transcriptional negative feedback is present but not utilised to compensate variations in Erk protein level. The bar graphs show the expression of several
classical dual-speciﬁcity phosphatases (DUSPs) measured using q-RT–PCR in comparison with the level in cells treated with control (DMSO or scrambled, in (A) or (B),
respectively). (A) DUSP5, 6, 7 are negative feedback regulators in LIM1215 cells, as treatment with high doses of the Mek inhibitor U0126 resulted in strong
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the signal originates from the mutated B-Raf, the feedback has
no effect in these cells (see also below).
To exclude that increaseof pMekafter Erk knockdownis not
due to feedback control of Ras in the Ras-mutated cells, we
measured Ras activity byan active Ras pulldown assay in cells
treated with AZD6244 for 2h, and compared these with
DMSO-treated cells. We ﬁnd that there is no increase of Ras
activation after abrogation of Erk activity in the Ras-mutated
cells, excluding negative feedback control upstream or at the
level of Ras in these cells harbouring a Ras mutation (see
Figure 4B).
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not due to other differences between the cell lines, we next
investigated cell lines with inducible forms of Raf. As a ﬁrst
model system, we experimented with HEK cells that express a
fusion protein of the catalytic domain of Raf-1 and the
oestrogen receptor-binding domain (Cagnol et al, 2006).
In these cells, Raf activity can be triggered by adding
4-hydroxytamoxifen (4OHT). The fusion protein lacks the
regulatory domain, and is therefore insensitive to feedback
regulation. pMek levels in 4OHT-treated cells do not increase
strongly after abrogation of Erk activity by the Mek inhibitor
(Figure 4C). Thus, MAPK signalling when triggered from Raf
that lacks the regulatory domain shows no other prominent
feedback. In contrast, if the cells are stimulated by FGF and
the Raf–ER fusion protein is not activated by 4OHT, the cells
display very strong feedback regulation, as pMek increases
strongly once the Mek inhibitor is applied (Figure 4C). As a
second model system, we used the colon cancer cell line
CaCo2, which we stably transfected with inducible mutated
B-Raf V600E, and cells with inducible wild-type B-Raf or an
empty expression vector as controls. Again, we measured
pMek levels in these cells after applying the Mek inhibitor or
vehicle controls. In line with our hypotheses, B-Raf-mutated
cells show no feedback regulation, as Mek inhibition does
not lead to an increase of pMek, while cells expressing
empty vector or overexpressing wild-type B-Raf show strong
feedback regulation.
Taken together, several lines of evidence suggest that ppErk
levels are controlled by a negative feedback at the level of
Raf-1. In order to investigate whether such negative feedback
sufﬁciently explains the observed robustness in ppErk level
towards perturbations of the total Erk concentration, we
further analysed the data using a mathematical model.
Mathematical analysis shows that feedback
is highly amplifying
In order to quantitatively analyse the feedback further, we
addedfeedbackinhibitionofMektothemodelofEquation(1):
ppErk
ErkT
¼
ðkpMekðppErkÞÞ
2
1 þð kpMekðppErkÞ Þþð kpMekðppErkÞÞ
2
pMek
pMek0
¼1   r1
ppErk
ppErk0
  1

:
ð8Þ
The subscript 0denotes pMekandppErklevelsin unperturbed
cells. k denotes the rate constant of phosphorylation by Mek
relativetothedephosphorylationrateconstant.Theparameter
r1 denotes the strength of the feedback, that is, the relative
change in phosphorylated Mek upon a relative change in
phosphorylated Erk. The parameter r1 can be interpreted in
terms of response analysis, where |r1|o1 denotes weak
feedback and |r1|41 amplifying, strong feedback.
In order to investigate whether the feedback model
sufﬁciently explains the data, we ﬁtted this model to the
measureddata points for the twocell lines HCT116and SW480
using a least-squares method. The best model ﬁt can explain
the data points well, as shown in Figure 5A. The parameter r1
was estimated to be 5.4 for HCT116 cells and 2.2 for SW480
cells.Therefore,themodelshowsthatthefeedbackfromErkto
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example, 10% results in B20% increase of pMek in SW480
cells and 50% in HCT116 cells.
Taken together, the mathematical analysis shows that
negative feedback from Erk to Raf-1 alone is sufﬁcient to
explain the observed robustness, and the lack of robustness in
B-Raf-mutated cells indicates that other mechanisms are not
utilised.
Robustness is not due to saturation of Mek
In the beginning, we hypothesised that competition for the
upstream kinase Mek might be a mechanism that causes
robustness.Since B-Raf-mutated cells do not showrobustness,
this mechanism is unlikely. Nevertheless, one could argue that
Mek levels in B-Raf-mutated cell lines might be different from
Mek levels in B-Raf wild-type cells, and Mek might be only
saturated in B-Raf wild-type cells. Therefore, we overex-
pressed Mek1 in SW480 cells, which have wild-type B-Raf and
showed robustnessagainst changes in Erk levels. If robustness
was due to limiting amount of Mek, ppErk would necessarily
behighlydependentonMeklevels.Incontrast, ifrobustnessis
solely dependent on negative feedback, Mek overexpression is
expected to have only little effect on ppErk.
The results are summarised in Figure 5B. Even strong
overexpression of Mek1 does not change the phosphorylation
of ppErk; therefore, saturation of pMek can be ruled out as a
mechanism that provides robustness in these cells.
Efﬁciency of small-molecule inhibitors is impaired
by strong negative feedback
Several small-molecule compounds have been developed to
target the kinase Mek, including the widely used experimental
Mek inhibitors U0126 and AZD6244, which is currently tested
in phase II clinical trials for different cancers. Both inhibitors
bind non-competitively with ATP, thus reaching high speciﬁ-
city for Mek (Yeh et al, 2007) with dissociation constants (KD-
values) in the low nanomolar range. Most likely, the inhibitors
bind to both active and non-active forms of Mek. Therefore,
the action of these pharmacological inhibitors can be included
in our model in the following way:
ppErk
ErkT
¼
ðkpMek
aðppErkÞÞ
2
1 þð kpMek
aðppErkÞ Þþð kpMek
aðppErkÞÞ
2
pMek
a
pMek0
¼ð1   IÞ 1   r1
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  1
 
:
ð9Þ
ThesuperscriptadenotestheconcentrationofactiveMek,that
is, the non-inhibitor bound, phosphorylated form of Mek. The
parameter I denotes the biochemical inhibitor efﬁciency,
which represents the fraction of Mek that is bound by the
inhibitor and thereby inactivated. Assuming that the inhibitor
binds independent of the phosphorylation state of Mek with a
low nanomolar dissociation constant, I is approximated by the
inhibitor concentration divided by the Mek concentration.
Using this model, we investigated how the effectiveness of
inhibitors is hampered by the presence of the strong negative
feedback in B-Raf wild-type cells. To describe the efﬁciency of
Mek inhibitors in feedback-intact cells, we simulate the
suppression of Erk phosphorylation at varying inhibitor
concentrations using the model above and the kinetic
parameters that we have determined for HCT116 and SW480
cells. To compare with B-Raf mutant cells, we repeat the
simulation where the feedback strength r1 is set to zero. The
resultsofthisanalysisareshowninFigure6A.Thesimulations
show that the efﬁciency of Mek inhibitors is strongly reduced
through feedback-mediated robustness of the pathway. The
model also shows that full inhibition of Mek will result in a
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HCT116 cells, respectively.
To conﬁrm that the post-translational negative feedback via
Raf-1 is active in cells harbouring wild-type B-Raf upon
application of the Mek inhibitor, we measured pMek levels
24h post-inhibition of the pathway. In line with our model,
pMek levels rise sharply when Mek is inhibited in B-Raf wild-
type cells, contrasted by no increase in B-Raf-mutated cells
(Figure 6B). Interestingly, there is a quantitative agreement of
the maximal levels of measured phospho-Mek and the
predicted maximal levels, with pMek showing a six-fold
increase in HCT116 and a three- to four-fold increase in
SW480. At inhibitor levels exceeding 20mM, phospho-Mek
levels drop in all cell lines, which cannot be explained by the
present model. The mechanism for this drop might be either
unspeciﬁc effects of the inhibitor, inhibition of Mek phosphor-
ylation at high doses, or indirect effects due to changed
phenotype of the cells.
Feedback is fast and does not require translation
or transcription
In our analysis, we investigated how the pathway adapts to
changes in protein concentrations. The protein concentra-
tion of Erk has been shown to change on a timescale larger
than cell-cycle time (Cohen-Saidon et al, 2009); therefore,
we investigated cells 48h post-perturbation. We found that
a single post-translational feedback mediates robustness.
As such post-translational feedbacks may act on much faster
timescales, we were interested in investigating how quickly
the feedback operates. In order to investigate this, we applied
the Mek inhibitor AZD6244 to the cells and measured
phosphorylated Mek at multiple timepoints after application
of the inhibitor. Figure 6C shows that Mek phosphorylation
rises within 1h post-inhibition, suggesting that the feedback
acts on the timescale of typical signalling kinetics (o1h), and
may therefore also buffer faster variations within the pathway.
Regulation on such timescale may occur through transcrip-
tional or translational mechanisms. There may, for example,
be kinases or phosphatases that aretranscriptionally regulated
and which regulate Raf or Mek phosphorylation. Other
potential regulators may include Sprouty proteins. We there-
fore investigated whether the action of the feedback requires
transcription or translation by investigating the feedback
dynamics using generic inhibitors of transcription and
translation. We measured phosphorylation of Mek in a time
seriesaftertreatmentwithMekinhibitorAZD6244eitheralone
orcombinedwithaninhibitoroftranscription(actinomycinD)
or translation (cycloheximide). Figure 6D shows that, in line
with our theory, in B-Raf-mutated cells no change of Mek
phosphorylation is observed when the inhibitor is applied.
Furthermore, treatment with inhibitors of transcription and
translation do not inﬂuence pMek levels. In Ras-mutated cells,
phosphorylation of Mek increases once the Mek inhibitor is
applied, and remains constant under vehicle control. Block of
either transcriptionortranslationdoes notchange the increase
ofphosphorylation ofMekafterapplicationofMekinhibitorin
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require synthesis of new proteins. Taken together, these data
strongly support that feedback regulation is purely mediated
by post-translational mechanisms.
Discussion
Robustness of cellular function in response to physiologically
relevant perturbations is a major characteristic of living
systems (Stelling et al, 2004). In order to analyse how robust
speciﬁc cellular systems are and which designs have been
evolved to provide robustness, it is important to identify the
kind of perturbation that a cell witnesses in vivo (Kitano,
2004). It becomes clear that noise in the expression of proteins
is one of the key perturbations that cellular function has to
withstand (Sigal et al, 2006). We therefore analysed how the
activity of one of the central signal transduction pathways, the
MAPK signal transduction pathway, is inﬂuenced by changes
in protein level. A kinetic model suggested that the active
double-phosphorylated form of the terminal kinase in the
pathway, Erk, would be linearly dependent on the concentra-
tion of the kinase. In stark contrast, we found experimentally
that the phosphorylated form is only weakly dependent on the
protein concentration.
We identiﬁed two mechanisms by mathematical analysis
that might account for robustness: saturation of the upstream
kinase and negativefeedback. The pathway is equipped with a
manifold of negative feedbacks at different levels, Erk reduces
the activity of various players at different levels upstream in
the pathway by phosphorylation, and additionally it induces
the expression of deactivating phosphatases (Amit et al, 2007;
Legewie et al, 2008; Kholodenko et al, 2010).
Weexpectedthatmultiplefeedbackswouldcontributetothe
observed robustness, and thereby it would be hard to dissect
the contribution of each feedback. By analysing cells with
different activating mutations in the pathway we found strong
robustness to perturbations in Erk levels when Ras is mutated,
and no robustness when B-Rafis mutated. To oursurprise, this
suggested that a single feedback from Erk to Raf is sufﬁcient to
explain the observed robustness. While we focused our
analysis on feedback to Raf-1, which is the predominantly
used isoform in colon cancer cells, additional feedback
regulation from Erk to B-Raf has been reported previously
(Brummer et al, 2003; Rushworth et al, 2006; Ritt et al, 2010).
However, cells with the V600E mutation lack feedback control
of B-Raf, as the V600E mutation locks B-Raf into its active
conformation(Wanetal,2004).Furthermore,thisoncoprotein
hasbypassedvariouspositiveregulatoryrequirementssuch as
Ras and 14-3-3 binding, which are discussed to be modulated
by ERK-mediated feedback (Brummer et al, 2006; Rushworth
et al, 2006; Ritt et al, 2010). Furthermore, the active confor-
mation renders B-Raf V600E also resistant against negative
feedback regulators such as Sprouty proteins (Tsavachidou
et al, 2004; Brady et al, 2009).
Interestingly, the post-translational feedback from Erk to
Raf-1 is relatively fast and acts on a timescale of 1h; thus,
it may also confer robustness to short-term signalling.
It has recently been shown that this feedback has profound
effects on the robustness of this signalling pathway 20min
post-stimulation,suggesting that the pathwayactsasa negative
feedback ampliﬁer (Sturm et al,2 0 1 0 ) .
We found that transcriptional feedback, for example via
phosphatases, is not involved in mediating robustness. This is
surprising, as intuitively one might think that variability
within the pathway that changes within days may be buffered
by slow feedback, which seems however not to be the case.
Therefore, the role of these feedbacks in the pathway remains
puzzling. One reason might be that strong transcriptional
feedback introduces further stochasticity.
Our analysis shows that feedback to Raf-1 is sufﬁcient for
robustness. However, we cannot exclude that other post-
translational feedbacks do also contribute to robustness. One
could speculate that the other post-translational feedbacks are
fail-save mechanisms, that is, that they could compensate for
the loss of the feedback domain in Raf-1. Another possibility is
that they actually mediate cross talk as the other feedback
targets, for example, SOS, Src and EGFR, also activate parallel
pathways. In addition, the transcriptional negative feedbacks,
which are a wide-spread phenomenon (Legewie et al, 2008),
may bemoreimportant inﬁne-tuning thelengthofresponse in
transient signalling to reduce noise in target gene expression
(Bluthgen, 2010). Also, they may have an important role in
buffering strong overactivation (Haigis et al, 2008).
In our study, we concentrated on steady-state signal
transduction. Such long-term signalling via Erk is important
for example in the context of G1-S transition (Yamamoto et al,
2006; Meloche and Pouyssegur, 2007). It is also interesting to
studytheconsequencesofheterogeneityofErklevelsonshort-
term signalling, that is, after stimulation with a growth
hormone. A recent analysis has shown that the feedback to
Raf-1 provides also robustness against inhibition of Mek for
short-term signalling (Sturm et al, 2010). However, since
phosphorylation levels are generally much higher after
stimulation, it may be that the feedback is not sufﬁcient and
may be to slow to compensate decreased Erk protein levels.
Thus, it may be that short-term signalling is very hetero-
geneous, but long-term signalling is not. In line with this
theory,animagingstudyhasshownthatnuclearaccumulation
in the ﬁrst phase after stimulation is proportional to basal
expression of Erk (Cohen-Saidon et al, 2009). These authors
suggest that the readout for transient, short-term signalling is
fold-change rather than absolute values, and that the down-
stream early transcriptional network interprets fold-change
rather than absolute values through feed-forward loops.
As a consequence of the negative feedback, we quantita-
tively predicted that targeted Mek inhibitors would be more
potent in cells with B-Raf mutation than in cells without B-Raf
mutation. There are several studies that investigate an
association between successful inhibition of cell growth by
non-ATP competitively binding Mek inhibitors with B-Raf
mutation status. A recent study showed that Mek inhibitors in
B-Raf (V600E)-mutated cells show similar success as in K-Ras-
mutated colon cancer cells (Yeh et al, 2009). In contrast, other
studiesshowthatincancerssuchasnon-smallcelllungcancer
and thyroid cancer a B-Raf V600E is required for success of
Mek inhibitors (Solit et al, 2006; Friday et al, 2008; Leboeuf
et al, 2008). Our results suggest that the differences between
cells with mutated and wild-type B-Raf will not be qualitative,
but more a quantitative difference. Our model predicts that in
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at higher doses will abrogate Erk signalling. However, due to
loss of negative feedback, B-Raf-mutated cells will respond at
lower doses.
Our study highlights the importance of understanding the
mechanisms by which signal transduction pathways buffer
gene expression noise. These evolved robustness mechanisms
will largely effect how the signal transduction network reacts
upon targeted inhibition. In the case of the MAPK signalling
pathway, robustness seems to be mediated by one feedback
alone.Therefore,oncethefeedbackisbroken,thesystemloses
robustness and can be readily modulated by low concentra-
tions of targeted inhibitors. In contrast, if the feedback is
intact, inhibition of the pathway is inefﬁcient. This ﬁnding
explains why Mek inhibition has shown little success in
the past in cancer treatment. However, it also shows that a
subgroup of patients with B-Raf mutation will likely beneﬁt,
and that due to the robustness of the healthy cells that have
no B-Raf mutation side effects might be minimal. We believe
that analysing robustness of other signalling pathways in
a similar way will be the key to devise efﬁcient targeted
interventions for these, and will unveil which mutations in the
pathway will break robustness and thereby open the door for
efﬁcient intervention.
Materials and methods
Cells and cell culture
The cell lines SW480, HCT116, HT29 and RKO were obtained from the
ATCC (American Type Culture Collection, UK). LIM1215 was kindly
provided by Professor John Mariadason (Ludwig Institute for Cancer
Research, Austin Hospital, Melbourne, Australia). Cell lines RKO and
LIM1215 were maintained in DEMEM (Dulbecco’s Modiﬁed Eagle’s
Medium, Lonza) supplemented with 10% fetal calf serum, 1%
ultraglutamine and 1% penicillin/streptomycin. SW480, HCT116 and
HT29 were cultured in L15 medium (Leibovitz’s Medium, Lonza)
supplemented with 10% fetal calf serum and 1% penicillin/strepto-
mycin. All cells were incubated in a humidiﬁed atmosphere of 5% CO2
in air at 371C. In order to establish an inducible expression system for
B-Raf,CaCo2cells,akindgiftofProfessorThomasBrabletz(Freiburg),
were transfected with AhdI-linearised pWHE 644, which was kindly
provided by Dr Christian Berens (Erlangen). This vector encodes the
doxycycline-inducible system components rtTA and rtTS (Danke et al,
2010). Following selection with puromycine (8mg/ml), a stable pool of
Caco2-tet cells expressing the rtTA and rtTS was subsequently
transfected with AhdI-linearised pTET/HAhBRAF-IRES-GFP-bsr vec-
tors and selected with blasticidine S (5mg/ml) and puromycine (5mg/
ml). The latter vector will be described in detail elsewhere (Herr et al,
under revision) and contains the bi-cistronic HA-BRAF-IRES-GFP
expression cassette from pMIG/HAhBRAF (Eisenhardt et al, 2010) that
encodes for hemaglutinine (HA)-tagged human B-Raf and green
ﬂuorescent protein (GFP). Cells transfected with pTET/-IRES-GFP-bsr
respond to doxycycline treatment with expression of GFPand serve as
negative control. HA-B-Raf expression was induced by addition of
doxycycline hyclate (Sigma; 2mg/ml ﬁnal concentration). HEK Raf-ER
cells were used for stimulation experiments. These cells express the
oestrogen receptor–Raf-1 fusion molecule, and were described
previously (Cagnol et al, 2006).
Transient transfection assays
For siRNA transfection, cell lines were plated 24h before siRNA
knockdown. Cells were either mock-transfected, scrambled-trans-
fected (ON-TARGETplus Non-targeting Pool negative control siRNA
with at least four mismatches to any human, mouse or rat gene;
Thermo Scientiﬁc Dharmacon) or transfected with 50nM Erk1
(siRNA pool using the following sequences from Invitrogen:
MAPK3HSS108538 GGAAGCCAUGAGAGAUGUCUACAUU, AAUGUA
GACAUCUCUCAUGGCUUCC; MAPK3HSS108539 GCAUUCUGGCUG
AGAUGCUCUCUAA, UUAGAGAGCAUCUCAGCCAGAAUGC; MAPK3H
SS108540 CCUGCUGGACCGGAUGUUAACCUUU, AAAGGUUAACAUC
CGGUCCAGCAGG), Erk2 (MAPK1HSS1085535 GCCGAAGCACCAUU
CAAGUUCGACA, UGUCGAACUUGAAUGGUGCUUCGGC; MAPK1HSS
1085536 UCACACAGGGUUCCUGACAGAAUAU, AUAUUCUGUCAGGA
ACCCUGUGUGA; MAPK1HSS1085537 GGGCUACACCAAGUCCAUU
GAUAUU, AAUAUCAAUGGACUUGGUGUAGCCC) siRNA or both for
Erk1/2 knockdown, further using lipofectamine 2000 or RNAi-Max
(both from Invitrogen) according to the manufacturer’s instructions.
Brieﬂy,7.5ml(15mlforscramble)siRNAand7.5mltransfectionreagent
were combined in a total of 500ml Opti-MemIþGlutamax-I (GIBCO).
The mix was incubated for 20min at room temperature before adding
the complexes dropwise to the cells. After 24h, cells were transfected
for a second time, followed by a medium change after 3–4h. RNA
and protein extracts were prepared 48h after second transfection.
siRNA experiments were repeated in minimum three times. For
overexpressionofMek1,SW480cellsweretransientlytransfectedwith
pMEV2HAMek1-WT vector or empty pcDNA3 as control (Biomyx
Technology) using lipofectamine 2000 (Invitrogen). Cells were
harvested and lysed 24h post-transfection.
RNA isolation and quantitative RT–PCR analysis
RNA was isolated from cells which were transiently siRNA trans-
fected (48h post-transfection) or treated 24h with 20mM U0126
using the RNeasy-mini-kit (Qiagen) according to the supplier’s
protocol. Quantitative real-time PCR analysis was performed using
a StepOnePlus 96-well format Light-Cycler apparatus (Applied
Biosystems). Experiments were run and analysed with the StepOne
2.0 software according to the manufacturer’s recommendations.
Synthesis of double-stranded DNA during the PCR cycles was
visualised with SYBR Green using QuantiTect SYBR Green RT–PCR
kit, (Qiagen). The following QuantiTect primer assays were used:
Hs_DUSP1_1_SG, Hs_DUSP2_1_SG, Hs_DUSP4-va.1_SG, Hs_DUSP5_
2_SG,Hs_DUSP6_1_SG, Hs_DUSP7_1_SG,Hs_DUSP8_1_SG, Hs_DUSP9_
1_SG, Hs_DUSP10_va.1_SG and Hs_DUSP16_1_SG. All samples were
run in triplicates and two biological replicates. Target expression
was quantiﬁed relatively to actin (Hs_ACTA1_1_SG) expression. We
measured standard calibration curves to conﬁrm that the PCRs had
full efﬁciency.
Immunoblotting
Protein extracts of cells were prepared by incubation with sodium
dodecyl sulphate (SDS)-cell lysis buffer (10% SDS, 1M Tris–HCl pH
7.5, EDTA 0.5M pH 8) or cell lysis buffer (Bio-Rad). Reagents for SDS–
polyacrylamide gel electrophoresis (PAGE) and western blotting were
obtained from Bio-Rad Laboratories (Richmond, CA, USA) and Carl
Roth (Karlsruhe, Germany). Electrophoresis was performed and
lysates were transferred onto nitrocellulose membranes (Schleicher
& Schu ¨ll). Unbound protein sites were blocked with 1:1 Li-COR buffer
in phosphate-buffered saline. Thereafter, speciﬁc proteins were
detected by incubation with primary antibodies diluted in 1:1 Li-COR
buffer/phosphate-buffered saline containing 0.1% Tween-20 (PBST)
overnight at 41C followed by near-infrared dye labelled secondary
antibodies. The following antibodies were used: rabbit anti-human
P-Erk1/2 (phospho-p44/42 MAPK Thr202/Tyr204, Cell Signaling
Technology, 1:500), rabbit anti-human Erk1/2 (p44/42-MAPK, Cell
Signaling Technology, 1:500), mouse anti-human Actin (Millipore,
1:5000or Santa CruzBiotechnology, 1:2000), rabbit anti-phospho-Raf-
1 (S289/S296/S301, Cell Signaling Technology, 1:1000), anti-pan-Ras
(Millipore, 1:200), rabbit anti-human Raf-1 C-12 (Santa Cruz
Biotechnology, 1:750), rabbit anti-human Tubulin (Cell Signaling
Technology, 1:2000) or mouse anti-human GAPDH (Ambion,
1:10000). Membraneswere scannedusing Li-COROdyssey. Thebands
were quantiﬁed by determining the integrated density using ImageJ
software (http://rsbweb.nih.gov/ij/) and subtracting the mean back-
groundintensitymultipliedbytheareaoftheband.Allintensitieswere
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relative to scramble controls. Since the pErk antibody detects the
highly conserved phosphorylation domain it displays equal afﬁnity to
ppErk1 and ppErk2 (Leﬂoch et al, 2008). Therefore, the sum of ppErk1
and ppErk2 bands is taken as total phosphorylation of Erk. Since the
Erk1/2 antibody shows different afﬁnities to the two isoforms, this
afﬁnity needs to be calibrated (Leﬂoch et al, 2008). We determined the
ratio ofafﬁnitiestoErk1 andErk2,respectively, bycomparing the ratio
of ppErk1/ppErk2 bands and Erk1/Erk2 bands from unperturbed cells
(embracing all conducted experiments). We found that the antibody
displayedalowerafﬁnitytoErk2thantoErk1(0.29±0.09).Therefore,
the amount of total Erk was calculated by scaling the intensity of the
Erk1 band with the factor 0.29, and adding it to the unscaled intensity
oftherespectiveErk2bands.ThedataconﬁrmingtheeffectoftheMEK
inhibitor on the feedback phosphorylation of Raf-1 were generated by
western blotting using a Fuji-LAS 4000 device as described previously
(Eisenhardt et al, 2010).
Bio-Plex assay
Cells were transfected with siRNA or treated with different concentra-
tions of U0126 (Promega), 1mM AZD6244 (Selleck Chemicals LLC),
10 mg/ml Cycloheximide (Calbiochem), 5mg/ml Actinomycin D
(Sigma), 50nM 4OHT or 0.005mg/ml FGF2 (Preprotech). After
incubation, lysates were collected and the level of phospho-protein
expression was analysed with the Bio-Plex Protein Array system (Bio-
Rad, Hercules, CA) using beads speciﬁc for P-Mek1 (S217/S221)
according to the manufacturer’s instructions. Brieﬂy, samples were
washed with PBS and lysed with cell lysis buffer (Bio-Rad). Lysate
protein concentration was determined with BCA (bicinchoninic acid)
method. The beads and detection antibodies were diluted 1:5. For
acquiring data, the Bio-Plex Manager software was used according to
the manufacturer’s instructions.
Ras activity assay
For the Ras activity assay, the active Ras pulldown and detection kit
from Thermo Scientiﬁc was used according to the manufacturer’s
instruction. Brieﬂy, cells were plated 24h prior treatment with AZD6244
for 2h. Cells were collected and lysed, and the lysate incubated with GST-
Raf-1-RBD, a GST fusion protein that contains the Ras-binding domain
of Raf-1. Using an immobilised gluthatione disc, the active Ras was
precipitated and detected by western blot using a Ras-speciﬁc antibody.
Mathematical modelling
The numerical simulations of models in Equations (8) and (9) were
done in Matlab, Version R2007b. Model equations for ppErk were
solved numerically using matlab function fzero. Parameter estimation
was performed by minimising the squared residuals using lsqnonlin.
Analytical calculations in this study were partially done using
Mathematica algebraic software.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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